Efficacy and Tolerability of Vascular Endothelial Growth Factor Receptor Inhibitors (VEGFRi) for Recurrent/Metastatic Adenoid Cystic Carcinoma (R/M ACC): a Systematic Review and Meta-Analysis
ACC has a high rate of recurrence and distant metastasis. There is no FDA-approved systemic therapy for R/M ACC. Given high VEGFA expression in ACC and association with poorer prognosis, various clinical trials have assessed VEGFRi in R/M ACC but are mostly single-arm studies with small sample sizes. The relatively low level of evidence has led to debate over the adoption of VEGFRi in ACC management. Given remaining uncertainty, we performed a systematic review and meta-analysis evaluating efficacy, safety, and tolerability of VEGFRi in R/M ACC.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: C.O. Hoff, J. Manzi, F. Lazar Neto, R. Ferrarotto Tags: 243 Source Type: research
More News: Adenoids | Biology | Cancer & Oncology | Carcinoma | Clinical Trials | Physics | Radiology | Study